AZT logo

ArcticZymes Technologies ASA Stock Price

OB:AZT Community·NOK 1.1b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

AZT Share Price Performance

NOK 20.60
6.68 (47.99%)
NOK 32.00
Fair Value
NOK 20.60
6.68 (47.99%)
35.6% undervalued intrinsic discount
NOK 32.00
Fair Value
Price NOK 20.60
AnalystConsensusTarget NOK 32.00

AZT Community Narratives

AnalystConsensusTarget·
Fair Value NOK 32 35.6% undervalued intrinsic discount

Precision Medicine Will Continue Advancing Through Biomanufacturing And Gene Therapies

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
NOK 32
35.6% undervalued intrinsic discount
Revenue
20.42% p.a.
Profit Margin
30.92%
Future PE
33.1x
Price in 2028
NOK 38.49

Trending Discussion

Updated Narratives

AZT logo

AZT: European Distribution Deal And Buyback Program Will Drive Future Upside

Fair Value: NOK 32 35.6% undervalued intrinsic discount
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

1 Risk
2 Rewards

ArcticZymes Technologies ASA Key Details

NOK 110.0m

Revenue

NOK 4.7m

Cost of Revenue

NOK 105.3m

Gross Profit

NOK 98.1m

Other Expenses

NOK 7.2m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 12, 2026
0.14
95.71%
6.55%
0%
View Full Analysis

About AZT

Founded
1990
Employees
53
CEO
Michael Akoh
WebsiteView website
www.arcticzymes.com

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools, such as research and diagnostics, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.

Recent AZT News & Updates

Recent updates

No updates